Johns Hopkins University and the Medicines Patient Pool (MPP) have signed a license agreement to facilitate the clinical development of the tuberculosis drug, sutezolid. Sutezolid, an oxazolidinone antibiotic in the same class as linezolid, has shown promise in use as a compound in early stage trials to be more potent and less toxic in the treatment of TB.
The CDC has recently published Modules 6 and 8 of the Self-Study Modules in Spanish. These Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The series consists of a total of nine modules that are separated into two courses. The first course, Modules 1-5, provides basic information on TB. The second course, Modules 6-9, provides more specific TB programmatic information.
Jointly sponsored by the Regional Training and Medical Consultation Centers, the course "Optimizing Outcomes of Drug-Resistant Tuberculosis in High-Resource, Low-Incidence Settings" will be offered as part of The Union-NAR End TB 2017 Conference in Vancouver, Canada.
This 3-hour training will provide an overview of the medical management and case management of drug-resistant tuberculosis including a discussion of diagnostics, treatment options, special situations, and a panel discussion with clinical and programmatic perspectives on the use of the short course MDR regimen in high-resource, low-incidence settings.
Location: Sheraton Vancouver Wall Centre
Date: February 22
Time: 12:00 p.m. - 3:00 p.m.
In an effort to accelerate progress towards ending TB, WHO’s Global TB Programme (GTB) has established the first Global TB Research Task Force.
The Task Force, comprising of 19 TB programme, research financing, technical, civil society and academic experts, chaired by Christine Sizemore, NIH/NIAID, met in Geneva from 8-9 December 2016. The goal was to identify strategies for WHO to promote and facilitate TB research, and speed-up translation of science ‘from bench to bedside’ to improve TB care and control at international and national levels. Drawing on both global and national research needs, the Task Force also advised on actions to address global funding for TB research and development in congruence with current global and national efforts.
The Centers for Disease Control and Prevention’s Division of Tuberculosis Elimination (DTBE) has partnered with Medscape, a leading online resource for physicians and healthcare professionals, to produce an expert video commentary featuring DTBE Director, Dr. Philip LoBue. The video provides information for physicians on the new U.S. Preventive Services Task Force recommendation for latent TB infection testing. Dr. LoBue discusses diagnosis and treatment guidelines, as well as available DTBE resources on latent TB infection.
The video is a great way to share information with private healthcare providers on the importance of latent TB infection testing and treatment. You can find the video online: http://www.medscape.com/viewarticle/873121?src=par_cdc_stm_mscpedt&faf=1
The World Health Organization (WHO) welcomes the United Nations (UN) General Assembly (GA) Resolution A/71/L.41 passed today, calling for the UNGA to hold the first-ever high-level meeting on the fight against tuberculosis (TB) in 2018.
WHO has been asked to work with the UN Secretary-General, in consultation with Member States, to conceptualize and plan the 2018 high-level meeting. The resolution also highlights the WHO Global Ministerial Conference on the fight against TB in the context of public health Sustainable Development Goals, which will be hosted by the Russian Federation in Moscow on 16-17 November 2017.
“This is a tremendous and unprecedented step forward by governments and all partners engaged in the fight against TB”, said Dr Mario Raviglione, Director of the WHO Global TB Programme. “The Ministerial Conference and the UNGA high-level meeting will be fundamental to drive efforts to end this top infectious killer. We look forward to working closely with the Office of the UN Secretary-General, in consultation with Member States, to ensure the meeting results in bold and innovative solutions. For that, the engagement of all partners will be crucial for the success of these meetings.”
WHO in its report this year announced that TB was one of the top 10 causes of death worldwide in 2015, responsible for more deaths than HIV and malaria. In the same year, an estimated 1.8 million people died from TB, of which 0.4 million were co-infected with HIV. Worldwide, 10.4 million people fell ill with TB. The report highlighted the need for countries to move much faster to prevent, detect, and treat the disease if they are to meet global targets.
World Health Organization
Global TB Programme
20, Avenue Appia, CH-1211,Geneva, Switzerland
Tel: (+41) 22 791 4695, Email: email@example.com
For more information please go to www.who.int/tb
Newly Published: 2016 Clinical Practice Guidelines for Diagnosis of Tuberculosis in Adults and Children
Just released by the CDC, the American Thoracic Society, and the Infectious Diseases Society of America, these guidelines provide recommendations on the diagnosis of latent TB infection, pulmonary TB, and extrapulmonary TB in adults and children, updating guidelines that were published in 2000.
The guidelines provide evidence-based recommendations that were developed with the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. GRADE involves structured literature review, systematic reviews and meta-analyses of combined data, and expert discussion to assess the certainty in the evidence and determine the strength of each recommendation.
The twenty-three evidence-based recommendations include guidance for clinicians on how to employ newer tests to diagnose TB disease and latent TB infection, including interferon-gamma release assays (IGRAs) and molecular diagnostics. Although TB is less common in the United States than in other parts of the world, clinicians should consider testing patients who have a higher-risk for TB infection, including patients who were born in or who frequently travel to countries where TB disease is common; patients who live or have lived in large group settings, such as homeless shelters or prisons and jails; or those with other risk factors, as described in the guidelines.
Earlier this year, the Centers for Disease Control and Prevention (CDC) released provisional 2015 surveillance data on reported tuberculosis (TB) cases in the United States. The full report, entitled Reported Tuberculosis in the United States, 2015, is now available online.
The first increase in TB cases in the United States in 23 years underscores the need for more comprehensive public health approaches in TB prevention and control. Eliminating TB in the United States requires an expanded approach to test and treat latent TB infection, and strengthen existing systems to stop TB transmission.
CDC has developed a slide set, fact sheet, infographic, and web graphics with highlights from the surveillance report to support TB education and outreach to clinicians, health care agencies, and community organizations.
View this webinar, 2016 ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis, which highlights the guidelines development process, the key changes in recommendations and discussion of evidence supporting the changes. This 90-minute presentation is directed toward physicians, nurses and other health professionals who treat and case manage patients with active TB. Sponsored by the five RTMCCs, the presentation was aired on November 4.
Link to Webinar
The 2017 National TB Conference is being held on April 18-21, 2017, at the Atlanta Marriott Marquis in Atlanta, GA, USA.
The National TB Conference welcomes the submission of abstracts for poster presentation on all aspects of tuberculosis control, including epidemiologic, clinical, basic science, nursing, social, behavioral, psychosocial, and educational as well as outcomes of program initiatives. Abstracts are due Tuesday, January 3, 2017 at 11:59 p.m.
The 2017 National TB Conference will kick off with an evening reception and poster discussion session on Tuesday, April 18 from 5:00-6:30 p.m. This session will be held in conjunction with our APHL colleagues.
More Information and Online Abstract Submission Form